Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
09/2003
09/18/2003CA2478369A1 Novel polypeptides having sequence similarity to gdnfr and nucleic acids encoding the same
09/18/2003CA2478338A1 Combination therapy for treating, preventing or managing proliferative disorders and cancers
09/18/2003CA2478317A1 Methods of preventing or treating disorders by administering an integrin .alpha.v.beta.3 antagonist in combination with an hmg-coa reductase inhibitor or a bisphosphonate
09/18/2003CA2478239A1 The prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents
09/18/2003CA2478177A1 Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
09/18/2003CA2478169A1 Human antibodies specific to kdr and uses thereof
09/18/2003CA2478121A1 Antibiotic composition
09/18/2003CA2478089A1 Methods and composition based on discovery of metabolism of nitroclycerin
09/18/2003CA2478087A1 Microtubule stabilizing compounds
09/18/2003CA2477982A1 Methods for entrapment of bioactive agent in a liposome or lipid complex
09/18/2003CA2477979A1 An inhalation system for treatment of intracellular infections
09/18/2003CA2477973A1 Methods for alzheimer's disease treatment and cognitive enhancement
09/18/2003CA2477701A1 Controlled release dosage forms
09/18/2003CA2477329A1 Controlled delivery patch of active ingredient
09/18/2003CA2477256A1 Methods for aneurysm repair
09/18/2003CA2476938A1 Compositions and methods for preventing and treating cancer via modulating ube1l, isg15 and/or ubp43
09/18/2003CA2476183A1 Treatment of type i diabetes mellitus using growth hormone antagonist
09/18/2003CA2474613A1 Sustained release drug formulations containing a carrier peptide
09/18/2003CA2472119A1 Screening method for orthopoxvirus antivirals
09/18/2003CA2459834A1 Citalopram for the treatment of elevated blood pressure
09/17/2003EP1344535A2 Combined angiotensin II antagonists and adrenaline receptor blockers for treatment of glaucoma
09/17/2003EP1344534A2 Combined angiotensin II antagonists and carbonic anhydrase inhibitors for treatment of glaucoma
09/17/2003EP1344524A1 Reflux inhibitors
09/17/2003EP1344063A1 A screening assay for antagonists of human leukocyte receptors
09/17/2003EP1343900A2 Oxidoreductases
09/17/2003EP1343890A2 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
09/17/2003EP1343888A2 Regulation of human chemokine-like receptor
09/17/2003EP1343887A2 Human transporter proteins, nucleic acid molecules encoding them, and uses thereof
09/17/2003EP1343886A2 Compositions and methods for the therapy and diagnosis of lung cancer
09/17/2003EP1343822A2 Means for the diagnosis and therapy of ctcl
09/17/2003EP1343820A1 Human anti-epidermal growth factor receptor single-chain antibodies
09/17/2003EP1343817A2 Novel treatment
09/17/2003EP1343807A2 Diaryl peptides as ns3-serine protease inhibitors of hepatits c virus
09/17/2003EP1343806A1 Methylene steroids as novel androgens
09/17/2003EP1343789A1 Tricyclic derivatives of indole with antiangiogenic activity
09/17/2003EP1343786A1 Novel pyridine-substituted pyrazolopyridine derivatives
09/17/2003EP1343769A1 Benzoylpyridazines
09/17/2003EP1343763A1 Pyrodone derivatives as ap2 inhibitors
09/17/2003EP1343760A2 Muscarinic antagonists
09/17/2003EP1343529A2 Nsaid formulations comprising lecithin oils for protecting the gastrointestinal tract and providing enhanced therapeutic activity
09/17/2003EP1343528A2 Methods for stimulating nervous system regeneration and repair by inhibition phosphodiesterase type 4
09/17/2003EP1343520A2 New therapeutic uses of smr1 peptides
09/17/2003EP1343519A2 Modulation of smr1-nep interactions in cns disorders giving rise to mental disorders
09/17/2003EP1343507A2 Method to treat infectious diseases and/or to enhance antimicrobial efficacy of drugs
09/17/2003EP1343506A1 Pharmaceutical formulation containing pyrazolo 4,3-d]pyrimidines and antithrombotic agents, calcium-antagonists, prostaglandins or prostaglandin derivatives
09/17/2003EP1343503A1 Heteroaryl urea neuropeptide y y5 receptor antagonists
09/17/2003EP1343502A2 Methods for inhibiting the transmission of hiv using topically applied substituted 6-benzyl-4-oxopyrimidines
09/17/2003EP1343501A1 Therapy for herpes neurological viral conditions utilizing 1,4-dihydropyridine calcium channel blockers
09/17/2003EP1343493A2 Use of(-) (3-halomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
09/17/2003EP1343492A2 Treatment of mucositis
09/17/2003EP1343491A2 Use of pericyte apoptosis inhibitors for treating and/or preventing diabetic retinopathy
09/17/2003EP1343489A2 Sterile bicarbonate-free dialysis concentrate solutions
09/17/2003EP1343488A1 Treatment of statin side effects
09/17/2003EP1343486A1 Pharmaceutical or cosmetic composition and use of a pkc inhibitor with an mmp inhibitor for inhibiting langerhans' cell migration
09/17/2003EP1343485A2 Lipid-based nitric oxide donors
09/17/2003EP1343475A2 Self forming, thermodynamically stable liposomes and their applications
09/17/2003EP1343470A2 Methods and compositions for protecting and restoring skin using selective mmp inhibitors
09/17/2003EP1230230B1 Indeno-dihydrothiazole derivatives, the production thereof and their use as anorectic medicaments
09/17/2003EP1200445B1 Thienopyranecarboxamide derivatives
09/17/2003EP1196411B1 Bradykinin b1 receptor antagonists
09/17/2003EP1187627B1 Uses of h-trek-1 polypeptides and polynucleotides encoding them
09/17/2003EP1169056B1 Caspase-8 inhibitors for immunosuppression.
09/17/2003EP1119529B1 Chemical constructs
09/17/2003EP1079828B1 Compositions comprising 5-hydroxyindole as a modulator of a nicotinic receptor
09/17/2003EP0766960B1 External preparations for treating dermatoses
09/17/2003EP0571613B1 Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
09/17/2003CN1443241A Isolated nucleic acid molecules which encode T cell inducible factors, or interleukin-21, proteins encoded, and uses thereof
09/17/2003CN1443197A Acid-modified arabinogalactan protein composition
09/17/2003CN1443187A Fused cyclic compounds as modulators of nuclear hormone receptor function
09/17/2003CN1443176A Valsartan salts
09/17/2003CN1443173A Substituted imidazoles as TAFI a inhibitors
09/17/2003CN1443162A New combination of serotonin agonist (5HT2) and antagonist (5HT6) as pharmaceutical formulation
09/17/2003CN1443085A Method for locating compounds which are suitable for treatment and/or prophylaxis of obesity
09/17/2003CN1443079A Polymeric conjugates of antitumor agents
09/17/2003CN1443074A Methods and compositions for inhibiting immunoglobulin-mediated reperfusion injury
09/17/2003CN1443068A Combinations of depepotidyl peptidase IV inhibitors and other antidiabetic agents for treatment of diabete mellitus
09/17/2003CN1443067A Analgesic and anti-inflammatory compositions containing cox-2 inhibitors
09/17/2003CN1443066A Use of dopamine D2/D3 receptor agonists to treat fibromyalgia
09/17/2003CN1443065A Pharmaceutical composition improved in peroral absorbability
09/17/2003CN1443064A Administration of thiol-based chemoprotectant compound
09/17/2003CN1121441C Method of detecting lung disease
09/17/2003CN1121239C Anti tumor biological product and preparing method
09/17/2003CN1121232C Pharmaceutical composition for treatment of herpes
09/17/2003CN1121224C Pharmaceutical composition comprising compound having anti Xa activity and platelet aggregation antagonist compound
09/17/2003CN1121217C Immunological compound
09/17/2003CN1121214C Use of alicyclic diamines as immunomodulators
09/16/2003US6622036 Method for classifying and treating physiologic brain imbalances using quantitative EEG
09/16/2003US6620853 Methods and compositions for prevention and treatment of restenosis with non-steroidal anti-inflammatory drugs
09/16/2003US6620852 Surgical lubricant comprising water, propylene oxide, chlorhexidene gluconate, acetic acid, lavender, propylene glycol, methyl cellulose and/or sodium acetate; epinephrine vasoconstrictor
09/16/2003US6620836 Administering melatonin and magnesium compound
09/16/2003US6620834 Medicinal compositions for treating colorectal cancer
09/16/2003US6620816 Method for treating tumors by the administration of tegafur, uracil, folinic acid, and cyclophosphamide
09/16/2003US6620802 Methods of treating mild cognitive impairment using a glucocorticoid-specific receptor antagonist
09/16/2003US6620798 Synergistic agents for enhancing tissue repair
09/16/2003US6620792 Monosialoganglioside GM1 or a derivative thereof, namely, the inner ester AGF2 and the methyl ester AGF4, suitable for the treatment of Parkinson's disease. A further object of the present invention is a therapy for Parkinson's Disease
09/16/2003US6620789 Compounds are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs
09/16/2003US6620784 Uses of VEGF-E
09/16/2003US6620779 Administering to an individual for tumor treatment a chemotherapeutically effective amount of antitumor agent carboplatin, and erythropoietin a hematocrit elevator which is administered befor or concurrently with antitumor agent
09/16/2003US6620587 Ribosome complexes as selection particles for in vitro display and evolution of proteins
09/16/2003US6620438 Arylglycinamide derivatives
1 ... 666 667 668 669 670 671 672 673 674 675 676 677 678 679 680 681 682 683 684 685 686 ... 1151